Cypre builds immune and stroma competent organoids that aim to recreate the complexity of disease in a standardized and high throughput screening format.
Disease: Patient-derived tumor cells (blue) or other disease-specific cell type
Stroma: Disease-associated fibroblasts (green) and ECM hydrogel
Immune: Peripheral blood mononuclear cells (PBMCs, red) activate and infiltrate in the presence of the disease. Maintenance of key immune phenotypes (T cell, B cell, M2 macrophage, NK cell)
Paving the way for NAMs
(New Approach Methods)
With over 90% of drugs failing in clinical trials, the time to modernize preclinical models and reduce animal testing is now.
At Cypre, we are proud to support the FDA’s shift away from animal models with our immune-integrated organoid platform.
